DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
KYMR Kymera Therapeutics
- 36.880
- +0.250+0.68%
Close Feb 14 16:00 ET
- 36.880
- 0.0000.00%
Post 16:52 ET
2.39BMarket Cap-15.76P/E (TTM)
37.790High36.360Low500.48KVolume36.990Open36.630Pre Close18.54MTurnover1.16%Turnover RatioLossP/E (Static)64.77MShares53.27052wk High2.67P/B1.60BFloat Cap29.24052wk Low--Dividend TTM43.35MShs Float91.920Historical High--Div YieldTTM3.90%Amplitude9.600Historical Low37.053Avg Price1Lot Size
Kymera Therapeutics News
Kymera Therapeutics | SCHEDULE 13G/A: Others
Kymera Therapeutics | 8-K: Current report
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mainolfi Nello
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jacobs Bruce N.
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Chiniara Ellen
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Esposito Pamela
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Atlas Venture Fund X, L.P.(6.4%),Atlas Venture Associates X, L.P.(6.4%), etc.
Kymera Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. ROWE PRICE ASSOCIATES, INC.(10.3%)
Kymera Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avoro Capital Advisors LLC(9.99%),Behzad Aghazadeh(9.99%)
Kymera Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-FMR LLC(7.933%),Abigail P. Johnson(7.933%)
Kymera Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Wellington Management Group LLP(7.17%),Wellington Group Holdings LLP(7.17%), etc.
Kymera Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Kymera Therapeutics | 10-Q: Q3 2024 Earnings Report
Kymera Therapeutics | 8-K: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Esposito Pamela
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144